Print ISSN:-2581-5555

Online ISSN:-2456-9542

CODEN : IIJCDU

Article History

Received : 18-11-2023

Accepted : 06-12-2023



Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 361

PDF Downloaded: 220


Sophora interrupta bedd., ameliorates doxorubicin induced myocardial necrosis by attenuation of oxidative stress and structural cardiomyocyte alterations in rats


Full Text PDF


Original Article

Author Details : Jyothi Basini*, Vandana Mallavarapu

Volume : 8, Issue : 4, Year : 2023

Article Page : 250-255

https://doi.org/10.18231/j.ijcaap.2023.040



Suggest article by email

Get Permission

Abstract

Aim: The present study aimed at investigating the cardioprotective activity of Sophora interrupta Bedd against doxorubicin induced myocardial necrosis by attenuation of oxidative stress and structural cardiomyocyte alterations in rats.
Materials and Methods: The experimental procedure was carried out with male Wistar rats inducing cardiotoxicity by administrating Doxorubicin in normal saline 3.750 mg/kg i.p on day 7, 14, 21 and 28 and treated with test extract of Sophora interrupta Bedd at a dose of 200 & 400 mg/kg, b.wt., per orally once daily for 28 days. The heart weight to body weight ratio was measured to evaluate the effect of extract on MI. The plasma was evaluated for the biochemical parameters and cardiac markers. Pro-oxidant & anti-oxidant levels were measured along with the histopathological examination of the heart.
Results: The test extractsSophora interrupta Bedd showed a significant (p< 0> Conclusion: The test extract of Sophora interrupta Bedd was beneficial for doxorubicin induced cardiotoxicity by ameliorating oxidative stress and restoring the abnormal structural changes in the heart tissue.
 
Keywords: Cardioprotective activity, Sophora interrupta Bedd, Doxorubicin



How to cite : Basini J, Mallavarapu V, Sophora interrupta bedd., ameliorates doxorubicin induced myocardial necrosis by attenuation of oxidative stress and structural cardiomyocyte alterations in rats. IP Int J Compr Adv Pharmacol 2023;8(4):250-255


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.